US biotech IPOs yield 55% as capital shifts from AI
Biotech offerings are delivering a 55% weighted average return, eclipsing a slumping broader IPO market as mega-mergers inject fresh capital into the sector.
US biotech and pharmaceutical IPOs are generating a weighted average return of 55% this year, sharply contrasting with a 4.4% weighted average loss for the broader US IPO market excluding blank-check companies. The outperformance marks a surprising pivot for 2026, a year initially expected to be dominated by artificial intelligence and aerospace deals.
The anticipated AI boom has faltered amid concerns of an overextended rally. Shares of the 10 companies behind the year's largest US offerings have slumped by a weighted average of 6.3%.
Biotech's momentum is largely fueled by a wave of mega-mergers that have replenished investor capital. Abbvie, GSK, and Vertex Pharmaceuticals have each announced acquisitions exceeding $10 billion in the past month, driving up sector valuations.
Major fund managers are actively pivoting toward healthcare allocations. “Right now, you have some of the largest fund families in the world that are reallocating and pushing more capital into healthcare and the returns in the small and mid-cap market has proven to investors there is a lot of upside,” said Seth Rubin, Stifel Financial Corp.’s global head of ECM.
A robust summer pipeline is forming as a result. At least six biotechs, led by CRISPR-based genetic medicines developer Scribe Therapeutics Inc., have filed for July and August debuts. Total sector proceeds have already surpassed $5 billion, triple last year's figure, anchored by Parabilis Medicines Inc.'s record $770.6 million offering.
Individual debut performances have been exceptional. Hair loss drug developer Veradermics Inc. has surged over 500% since February, making it the top-performing US IPO of 2026 across all sectors. Blood disorder specialist Hemab Therapeutics Holdings Inc. follows as the second-best, having more than doubled since its IPO in May.
The volume of listings has already surpassed 2025's total of eight, though it remains well below the unsustainable pandemic-era peaks of 2020 and 2021. The Nasdaq Biotechnology Index has climbed 13% this year, supported by stable regulation and notable clinical breakthroughs.
The primary macroeconomic risk remains a higher-for-longer interest rate environment, which historically pressures the present value of biotech cash flows. However, the sector is currently trading independently of those headwinds.
Market participants argue the current valuations are justified by fundamentals rather than speculative excess. “You have to park your money somewhere and relative to other opportunities right now biotech feels like it’s not just a safe place, but a place that has real upside,” said Jack Bannister, senior managing director in equity capital markets at Leerink Partners.
